Teva Appoints Dr. Angus Grant, Ph.D., as EVP, Business Development. Dr. Grant will begin his employment on August 1, 2023, and will be based out of Teva’s US headquarters in Parsippany, NJ.
Dr. Grant comes to Teva with over 25 years of experience in the worldwide pharmaceutical and biotech business, with a proven track record in areas such as Business Development, R&D, and Regulatory Affairs.
Dr. Grant was most recently the Chief Business Executive of BeiGene, where he was in charge of business growth, clinical and business insights and valuation, investments and collaborations, and alliance management. Dr Grant was previously the CEO of the Dementia Discovery firm (DDF), a specialised venture capital firm focused on treatments for age-related dementias and neurodegenerative disease.
Dr. Grant formerly spent 12 years at Celgene, where he held numerous leadership positions such as Corporate Vice President of Business Development and Vice President, Regulatory Affairs.
Richard Francis, Teva’s President and CEO said: “We are pleased to welcome a leader of Angus caliber to our executive team at Teva. With a distinguished career spanning over more than two and a half decades in the global pharmaceutical and biotech industry, his breadth of experience and demonstrated expertise in business development, innovative R&D, and scientific affairs will be a significant asset to our organization.
Mr. Francis continued: “These are exciting times at Teva, as we embark on our Pivot to Growth strategy, a crucial element of which involves amplifying our innovation through our already promising pipeline as well as fortifying our business development endeavors. I have full confidence in Angus leadership and firmly believe that he is exceptionally positioned to lead the business development efforts during this era of transformation. His contributions will be instrumental in driving external innovation, fostering collaborations across academia, biotech, and pharmaceutical sectors, and enhancing Teva’s momentum in bringing innovative therapies to patients worldwide.”
Dr. Grant stated, “I am thrilled to be joining Teva’s executive leadership team and am inspired by Teva’s purpose and strategy to drive growth by stepping up and leaning more into innovation. I am looking forward to work with the extended Teva team and leading the excellent business development team, to drive innovation and to partner with the best minds in academia and the industry to bring meaningful impact and value for patients worldwide and for Teva.”
Dr. Angus Grant’s Bio:
Angus previously held executive positions at BeiGene, a worldwide, commercial-stage biotechnology business, where he oversaw Strategy and Partnership. Angus previously held top executive positions at Celgene and the Dementia Discovery firm (DDF), a specialised venture capital firm focused on treatments for age-related dementias and neurodegenerative illness.
Dr. Grant formerly held positions in business development and regulatory affairs at Novartis, Merck KGaA, Rhone Poulanc-Rohrer, and SmithKline Beecham. After earning his PhD in Anatomy/Immunology, Angus worked in a clinical laboratory at the National Institutes of Health before joining the FDA, where he focused on cell and gene therapy IND processing.
Angus joined Celgene in 2006 and occupied different positions of leadership over the next 12 years, including Corporate VP Business Development. Angus oversaw transactions ranging from R&D and commercialization collaborations through early equity investments, supply collaborations, M&A such as the $9 billion Juno acquisition in 2018, and worldwide and regional licencing.
Angus left Celgene to become CEO of Dementia Discovery Fund (DDF), inspired by their mission to invest in and build the early-stage biotech companies most likely to develop transformative treatments for neurodegenerative diseases, for the benefit of the millions of people suffering from this 21st-century health crisis that has long been untreated.
Dr. Grant earned his bachelor’s degree at the University of Richmond, his Ph.D. in anatomy and immunology at the Medical College of Virginia, and his postdoctoral studies at the National Cancer Institute. Dr. Grant is now the Chairman of the Board of Directors of Toronto Innovation and Acceleration Partners. He is a published scientist, having co-authored over 15 peer-reviewed scientific journal articles.
